Cat. No.: DAB-0011725
Product Information | |
---|---|
Clonality | Monoclonal |
Isotype | IgG |
Host Species | Rabbit |
Reactivity | Human, Mouse, Rat |
Applications | WB |
Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro46 of human ALAD protein. |
Format | Liquid |
Purity | Affinity purity |
Target Information | |
---|---|
Target Name | ALAD |
UniProt No. | P13716 |
Gene ID | 210 |
Gene Description | Delta-aminolevulinic acid dehydratase catalyzes the second step in heme biosynthesis. ALAD is also an endogenous inhibitor of the 26S proteasome. Defects in ALAD cause acute hepatic porphyria, an inherited defect in heme biosynthesis in the liver. ALAD activity is inhibited by lead, and defects in ALAD result in sensitivity to lead poisoning. Reduced expression of ALAD is associated with poor prognosis in breast cancer patients. Overexpression of ALAD in breast cancer cells negatively regulates proliferation, invasion, and transforming growth factor-β -mediated epithelial-mesenchymal transition . |
Shipping & Storage | |
---|---|
Shipping | Shipped at 4 °C. |
Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.